Transplants | Company & Drug | Global | 2020

launch Related Market Assessment Reports

• Hepatitis B Virus – Geographic Focus: China – Hepatitis B Virus – China In-Depth – China

  July 2023

  The prevalence of HBV is a major public health concern in China. Patients chronically infected with HBV are at high risk of developing hepatic cirrhosis and hepatocellular carcinoma. The majority…

• Renal Cell Carcinoma – Current Treatment – Detailed, Expanded Analysis (US)

  June 2023

  The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the treatment of this disease. In 2021, Keytruda (Merck & Co.) became the first…

• Kidney Transplant – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis (US)

  April 2023

  Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, transplant…

• Heart Failure – Geographic Focus: China – Heart Failure | China In-Depth | China

  December 2022

  Heart failure presents a major public health burden in China. With a rapidly rising urban population and a growing trend of unhealthy lifestyle, heart failure is expected to affect a sizeable…

• Neuromyelitis Optica Spectrum Disorder (NMOSD) – Epidemiology – Mature Markets

  November 2022

  Clarivate Epidemiology’s coverage of neuromyelitis optica spectrum disorder (NMOSD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…